23-valent pneumococcal polysaccharide vaccine and the risk of renal progression in older patients with chronic kidney disease.

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) ensures favorable outcomes and reduces the risk of cardiac events in patients on dialysis. However, the effect of PPSV23 vaccination on renal function remains unknown, particularly in patients with chronic kidney disease (CKD). Therefore, we investigated the association between PPSV23 efficacy and renal progression in older patients (age ≥ 75 years) with CKD. This multicenter, longitudinal cohort study was conducted using data (2008–2016) from the Epidemiology and Risk Factors Surveillance of CKD database. This database was associated with Taiwan's National Health Insurance Research Database (for period: 2008–2019). A total of 1195 older patients with CKD were recruited from 14 hospitals and communities across Taiwan. Renal progression was defined as a > 25% reduction in estimated glomerular filtration rate from the baseline value. A significant reduction in the risk of renal progression was observed in patients who had received PPSV23 (adjusted hazard ratio [HR]: 0.57; 95% confidence interval [CI]: 0.35–0.91). However, when stratified by CKD stage, this significant reduction was observed in patients with early-stage CKD but not in those with late-stage CKD. Furthermore, a significant reduction in the risk of renal progression was noted in male patients and those with hypertension. Our findings support the protective effect of PPSV23 against renal deterioration in older patients with CKD. • This study shows that PPSV23 can mitigate renal deterioration in older CKD patients. • PPSV23 could reduce the risk of renal progression, particularly in early-stage CKD. • PPSV23 benefits in reducing renal progression are observed in men but not in women. • PPSV23 markedly reduces renal decline in patients with both CKD and hypertension. [ABSTRACT FROM AUTHOR]